CIK 1595851
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2024-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 84.79% | 44 |
| Unclassified | 14.50% | 6 |
| Life Sciences Tools & Services | 0.72% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BIOHAVEN LTD | Unclassified | 5.94% | |
| 2 | SRPT | Sarepta Therapeutics, Inc. | Health Care | 5.11% |
| 3 | NVO | NOVO NORDISK A S | Health Care | 4.47% |
| 4 | BLUEPRINT MEDICINES CORP | Unclassified | 4.42% | |
| 5 | AXSM | Axsome Therapeutics, Inc. | Health Care | 4.14% |
| 6 | TARS | Tarsus Pharmaceuticals, Inc. | Health Care | 3.93% |
| 7 | CATX | Perspective Therapeutics, Inc. | Health Care | 3.41% |
| 8 | CGON | CG Oncology, Inc. | Health Care | 3.22% |
| 9 | ROIV | Roivant Sciences Ltd. | Health Care | 3.15% |
| 10 | PCVX | Vaxcyte, Inc. | Health Care | 3.12% |
45/51 names classified · sector 85.5% of weight · industry 85.5% · mkt cap 78.4%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 85.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 2% of book weight classified — the grid is NOT representative of the whole book.
Classified: 2.5% of book weight (1/47 names) · unclassified 97.5%: , SRPT, NVO, AXSM, TARS, CATX, CGON, ROIV, PCVX, VKTX +36 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BIOHAVEN LTD | 348,778 | $17M | 5.9% | NEW |
| 2 | SRPTSAREPTA THERAPEUTICS INC | 120,000 | $15M | 5.1% | ADD 118% |
| 3 | NVONOVO-NORDISK A S | 110,000 | $13M | 4.5% | NEW |
| 4 | BLUEPRINT MEDICINES CORP | 140,000 | $13M | 4.4% | ADD 250% |
| 5 | AXSMAXSOME THERAPEUTICS INC. | 135,000 | $12M | 4.1% | TRIM −10% |
| 6 | TARSTARSUS PHARMACEUTICALS INC | 350,000 | $12M | 3.9% | ADD 49% |
| 7 | CATXPERSPECTIVE THERAPEUTICS INC | 750,000 | $10M | 3.4% | TRIM −19% |
| 8 | CGONCG ONCOLOGY INC | 250,000 | $9M | 3.2% | TRIM −4% |
| 9 | ROIVROIVANT SCIENCES LTD | 800,000 | $9M | 3.1% | TRIM −20% |
| 10 | PCVXVAXCYTE INC | 80,000 | $9M | 3.1% | TRIM −47% |
| 11 | VKTXVIKING THERAPEUTICS INC | 140,000 | $9M | 3.0% | ADD 47% |
| 12 | SNDXSYNDAX PHARMACEUTICALS INC | 450,000 | $9M | 3.0% | ADD 29% |
| 13 | JANXJANUX THERAPEUTICS INC | 190,000 | $9M | 2.9% | ADD 280% |
| 14 | ASNDASCENDIS PHARMA A/S | 52,500 | $8M | 2.7% | TRIM −39% |
| 15 | CRNXCRINETICS PHARMACEUTICALS IN | 150,000 | $8M | 2.6% | TRIM −38% |
| 16 | SOLENO THERAPEUTICS INC | 150,000 | $8M | 2.6% | TRIM −50% |
| 17 | TGTXTG THERAPEUTICS INC | 310,000 | $7M | 2.5% | TRIM −38% |
| 18 | RZLTREZOLUTE INC | 1,474,995 | $7M | 2.4% | ADD 4% |
| 19 | PHATPHATHOM PHARMACEUTICALS INC | 375,000 | $7M | 2.3% | TRIM −38% |
| 20 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 128,411 | $6M | 2.2% | TRIM −57% |
| 21 | OLMAOLEMA PHARMACEUTICALS INC | 535,000 | $6M | 2.2% | TRIM −3% |
| 22 | IMVTIMMUNOVANT INC | 215,000 | $6M | 2.1% | TRIM −17% |
| 23 | INSMINSMED INC | 75,000 | $5M | 1.9% | ADD 15% |
| 24 | EWTXEDGEWISE THERAPEUTICS INC | 195,000 | $5M | 1.8% | NEW |
| 25 | REPLREPLIMUNE GROUP INC | 450,000 | $5M | 1.7% | HOLD |
| 26 | BBIOBRIDGEBIO PHARMA INC | 175,000 | $4M | 1.5% | ADD 25% |
| 27 | TSHATAYSHA GENE THERAPIES INC | 2,150,000 | $4M | 1.5% | ADD 72% |
| 28 | RYTMRHYTHM PHARMACEUTICALS INC | 78,842 | $4M | 1.4% | TRIM −33% |
| 29 | ANNXANNEXON INC | 650,000 | $4M | 1.3% | ADD 110% |
| 30 | KRROKORRO BIO INC | 110,000 | $4M | 1.3% | ADD 10% |
| 31 | DYNDYNE THERAPEUTICS INC | 100,000 | $4M | 1.2% | NEW |
| 32 | ARVNARVINAS INC | 145,000 | $4M | 1.2% | ADD 93% |
| 33 | CRBPCORBUS PHARMACEUTICALS HLDGS | 160,000 | $3M | 1.1% | TRIM −9% |
| 34 | BBOTHELIX ACQUISITION CORP II | 300,000 | $3M | 1.1% | HOLD |
| 35 | NUVBNUVATION BIO INC | 1,350,000 | $3M | 1.1% | ADD 17% |
| 36 | SVRASAVARA INC | 725,000 | $3M | 1.0% | TRIM −31% |
| 37 | TNYATENAYA THERAPEUTICS INC | 1,500,000 | $3M | 1.0% | ADD 11% |
| 38 | RGNXREGENXBIO INC | 265,000 | $3M | 0.9% | ADD 56% |
| 39 | CRVSCORVUS PHARMACEUTICALS INC | 500,000 | $3M | 0.9% | NEW |
| 40 | ABSIABSCI CORPORATION | 550,000 | $2M | 0.7% | NEW |
| 41 | NGNENEUROGENE INC | 50,000 | $2M | 0.7% | TRIM −29% |
| 42 | CAPRCAPRICOR THERAPEUTICS INC | 125,000 | $2M | 0.6% | NEW |
| 43 | APELLIS PHARMACEUTICALS INC | 65,000 | $2M | 0.6% | TRIM −52% |
| 44 | SMMTSUMMIT THERAPEUTICS INC | 85,000 | $2M | 0.6% | NEW |
| 45 | SYRESPYRE THERAPEUTICS INC | 60,000 | $2M | 0.6% | TRIM −76% |
| 46 | VRDNVIRIDIAN THERAPEUTICS INC | 75,000 | $2M | 0.6% | TRIM −87% |
| 47 | PRQRPROQR THRAPEUTICS N V | 887,700 | $2M | 0.6% | HOLD |
| 48 | ATYRATYR PHARMA INC | 800,000 | $1M | 0.5% | HOLD |
| 49 | LRMRLARIMAR THERAPEUTICS INC | 200,000 | $1M | 0.4% | NEW |
| 50 | ENGENE HOLDINGS INC | 160,898 | $1M | 0.4% | TRIM −62% |
| 51 | AMLXAMYLYX PHARMACEUTICALS INC | 325,000 | $1M | 0.4% | NEW |
Where this firm's principals came from and which firms its alumni went on to found.
